← Leaderboards
Lao-Tzu Allan-Blitz
Brigham And Women'S Hospital
$387,618
Attributed
$387,618
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $195.5K · FY2024–25$200K$150K$100K$50K$0
'24
'25
Funding mix
By agency
NIH$387,618 · 1
By mechanism
K23$387,618 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Yonatan H Grad$6,107,724
- Hadi Shafiee$15,983,059
- Sophia Koo$15,534,982
- Samuel M Behar$34,926,005
- Holly Elizabeth Rawizza$3,045,812
Others in their field
Other Rising Stars on “Acceptability And Feasibility”
- Schenita D. Randolph · Duke University$3,870,187
- Saeed Ahmed · Baylor College Of Medicine$3,372,206
- Tanya L Zakrison · University Of Chicago$3,254,872
- Czarina Navos Behrends · Weill Medical Coll Of Cornell Univ$3,156,884
- Keith Copelin Ferdinand · Tulane University Of Louisiana$2,797,027
- Heather Zierhut · University Of Minnesota$2,600,212
Research focus
Acceptability And FeasibilityAcquired Immunodeficiency SyndromeAdverse OutcomeAfricaAgreementAntibioticsAntimicrobial ResistanceAnti-Microbial SusceptibilityAreaAssay DevelopmentAutomobile DrivingBioinformaticsBlindnessBotswanaCareerCareer DevelopmentCefiximeCephalosporin ResistanceCephalosporinsCiprofloxacinClinicClustered Regularly Interspaced Short Palindromic RepeatsCodon NucleotidesAcceleration
Grant awards (3)
The development & pilot implementation of a Cas13a-based low-cost point-of-care assay for detecting Neisseria gonorrhoeae and molecular markers of antimicrobial resistance in resource-limited settings$192,137
K23 · FY2025 · AI · contact PI
The development & pilot implementation of a Cas13a-based low-cost point-of-care assay for detecting Neisseria gonorrhoeae and molecular markers of antimicrobial resistance in resource-limited settings$1
K23 · FY2025 · AI · contact PI
The development & pilot implementation of a Cas13a-based low-cost point-of-care assay for detecting Neisseria gonorrhoeae and molecular markers of antimicrobial resistance in resource-limited settings$195,480
K23 · FY2024 · AI · contact PI